Health technology assessment (HTA)
Overview Between January 2025 and June 2026, 20 medicinal products entered the EU Joint Clinical Assessment (JCA) process, including seven medicines developed primarily by Chinese companies. These products represent [...]
The latest HTADock R&D Briefing examines HTA outcomes and timelines for new active substances reviewed between 2021 and 2025 by 12 HTA agencies across Australia, Canada, Europe, and the [...]
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes in the Asia-Pacific.
Baseline mapping of national HTA authorities across the EU and EEA The EU Health Technology Assessment Regulation (HTAR) has moved from policy to practice, with Joint Clinical Assessments (JCAs) [...]
Overview Health technology assessment (HTA) plays a key role in supporting evidence-informed healthcare decision making, pricing, reimbursement, and coverage decisions worldwide. As countries seek to strengthen health policy and [...]
A CIRS-Utrecht University workshop explored different stakeholders' early experiences of Joint Clinical Assessment (JCA), considering practical implementation of JCA outputs into national HTA decision making. Download the full [...]
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes in the Asia-Pacific.
As pharmaceutical innovation becomes increasingly global, companies are pursuing multi-jurisdictional approvals and timely patient access through evolving regulatory and reimbursement pathways. In China, regulatory reforms and expanded use of [...]
A CIRS-Utrecht University workshop explored different stakeholders' early experiences of Joint Clinical Assessment (JCA), considering practical implementation of JCA outputs into national HTA decision making. Background [...]
As companies navigate diverse global HTA environments, new CIRS analysis provides timely evidence on the role of parallel regulatory/HTA submissions. Our latest publication in the International Journal of Technology [...]
